Cephalon employees should brace for layoffs, in part because management is already promising some jobs will go and because the impending merger with Teva doesn’t solve either company’s strategic problems.
None of this will worry CEO J. Kevin Buchi, however. He will walk out the door with a $5 million bonus after less than four months on the job.